Durect Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 5/14/2025)
| Balance Sheet | Total Assets | 18,349,000.00 | ROE | – |
| Balance Sheet | Total Equity | 9,131,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -1.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -19,086,000.00 | – | – |
| Cashflow | Operating Cash Flow | -19,086,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.27 | Div. Yield | – |
| Income | Net Income | -8,324,000.00 | P/E | – |
| Income | Shares Outstanding | 30,940,000.00 | P/B | – |
| Income | Total Revenue | 2,031,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company´s product pipeline, as of December 31, 2012, consisted of eight investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), with one program in Phase III with an NDA in preparation, two programs in Phase II and three programs in Phase I. The Company´s products candidates include Remoxy, POSIDUR, ELADUR, TRANSDUR-Sufentanil, Relday, ORADUR-based opioid, ORADUR-ADHD, Relday and other products. The Company´s developments are focused on the application of its drug delivery technologies to potential products in a variety of chronic and episodic disease areas, including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.durect.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more